CHELMSFORD, Mass.--(BUSINESS WIRE)--In a press release issued on November 18, 2009, ZOLL Medical Corporation (NasdaqGS: ZOLL - News) incorrectly stated that it was the exclusive intravascular temperature management solution available on the Federal Supply Schedule. Information has come to our attention that we are not the exclusive intravascular temperature management solution on the Federal Supply Schedule. We regret the error.
About ZOLL Medical Corporation
ZOLL Medical Corporation develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies which help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.
A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company for the past three years, ZOLL develops and manufactures its products in the United States, in California, Colorado, Illinois, Massachusetts, Pennsylvania, and Rhode Island. More than 400 direct sales and service representatives, 1,100 business partners, and 200 independent representatives serve our customers in over 140 countries around the globe. For more information, visit www.zoll.com.
Certain statements contained in this press release, including statements regarding the future business of the Company, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2009. You should not place undue reliance on the forward-looking statements in this press release, and the Company disavows any obligation to update or supplement those statements in the event of any changes in the facts, circumstances, or expectations that underlie those statements.
Copyright © 2009 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. ZOLL, CoolGard and Thermogard XP are registered trademarks of ZOLL Medical Corporation. IVTM is a trademark of ZOLL Medical Corporation.
Contact:
ZOLL Medical Corporation INVESTOR CONTACT: A. Ernest Whiton, +1 978-421-9655 Chief Financial Officer or MEDIA CONTACT: Diane Egan, +1 978-421-9637 degan@zoll.com
